Human Immunodeficiency Virus Therapeutics Industry Growth Insights: Revenue Forecast to 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the human immunodeficiency virus therapeutics market from 2026–2035 with trusted insights from The Business Research Company
What upper market value could the Human Immunodeficiency Virus Therapeutics Market reach by 2030 starting from 2026 levels?
The human immunodeficiency virus therapeutics market size has experienced robust expansion in recent years. Projections indicate it will grow from $14.9 billion in 2025 to $15.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.6%. The historical growth in this market stems from several factors, including the global burden of hiv infections, widespread adoption of antiretroviral therapy, government-funded hiv treatment programs, increasing availability of generic hiv drugs, and improved survival rates among hiv patients.
The human immunodeficiency virus therapeutics market size is projected to experience robust expansion over the coming years, reaching $19.4 billion by 2030, at a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is driven by factors such as the increasing demand for long-acting HIV therapeutics, a sharpened focus on personalized HIV treatment regimens, broader access to HIV treatment in low and middle income countries, increased investments in next-generation antiretroviral drugs, and a greater emphasis on lifelong HIV disease management. Significant trends within this forecast period include the wider adoption of combination antiretroviral therapies, a growing shift towards long-acting injectable HIV treatments, an intensified focus on early and sustained viral suppression, the increased availability of generic antiretroviral drugs, and an elevated emphasis on treatment adherence along with simplified regimens.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp
Which Drivers Are Influencing Long-Term Growth In The Human Immunodeficiency Virus Therapeutics Market?
The human immunodeficiency virus therapeutics market is anticipated to expand due to the increasing incidence of unprotected sexual practices. These practices involve engaging in sexual acts without barrier contraception, which elevates the likelihood of sexually transmitted infections (STIs) and unplanned pregnancies. A deficiency in thorough sex education results in inadequate knowledge regarding safe practices, thereby escalating risky conduct among young individuals. By suppressing the viral load to undetectable levels, human immunodeficiency virus therapeutics play a role in lowering the danger of HIV transmission stemming from unprotected sexual activities, consequently halting the infection’s progression. A relevant example is found in November 2024, where data from the Centers for Disease Control and Prevention, a US-based government agency, indicated that a 2023 survey of U.S. high school students revealed 32% had engaged in sexual intercourse at least once, and 48% did not use a condom during their most recent sexual encounter. Consequently, the expanding occurrence of unprotected sexual practices is fueling the growth of the human immunodeficiency virus therapeutics market.
Which Segments Are Driving Activity In The Human Immunodeficiency Virus Therapeutics Market?
The human immunodeficiency virus therapeutics market covered in this report is segmented –
1) By Drug Type: Branded Drugs, Generic Drugs
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By End-user: Hospitals And Clinics, Specialty Centers
Subsegments:
1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista
2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir
What Trends Are Driving The Growth Trajectory Of The Human Immunodeficiency Virus Therapeutics Market?
Major companies in the Human Immunodeficiency Virus Therapeutics market are concentrating on the creation of long-lasting, highly effective options for prevention and treatment, improving accessibility through supportive reimbursement schemes, and advancing innovative clinical strategies to enhance patient adherence and decrease new HIV infections. For example, in June 2025, Gilead Sciences, a US-based healthcare company, secured FDA approval for Yeztugo (lenacapavir), recognized as the first and only twice-yearly injectable PrEP option, signifying a substantial breakthrough in HIV prevention. Drawing on data from Phase 3 PURPOSE 1 and PURPOSE 2, the drug exhibited exceptional efficacy, with ≥99.9% of participants remaining HIV-negative. This long-acting injection aims to overcome existing challenges such as adherence difficulties, societal stigma, and limited awareness that impede current PrEP utilization. The approval of Yeztugo provides a promising instrument to aid in reducing new HIV infections across various populations. Additionally, Gilead is implementing extensive access initiatives, which include partnerships with insurance providers, co-payment assistance for eligible patients, and free access for uninsured individuals through specific assistance programs.
Which Key Market Players Are Investing In Expansion And Innovation Within The Human Immunodeficiency Virus Therapeutics Market?
Major companies operating in the human immunodeficiency virus therapeutics market are Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy’s Laboratories Ltd., Mylan N.V.
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Human Immunodeficiency Virus Therapeutics Market In The Coming Years?
North America was the largest region in the human immunodeficiency virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Human Immunodeficiency Virus Therapeutics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp
Browse Through More Reports Similar to the Global Human Immunodeficiency Virus Therapeutics Market 2026, By The Business Research Company
Human Immunodeficiency Virus Hiv Diagnosis Market Report 2026
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Infectious Disease Therapeutics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
